Natural Method for Clearing Cellular Debris Inspires Lupus Treatment
|
By LabMedica International staff writers Posted on 06 Mar 2012 |
Cells that die naturally generate a large amount of internal debris that can trigger the immune system to attack the body, leading to diseases such as lupus. Now, researchers report that an enzyme known to help keep a woman’s immune system from attacking a fetus also helps block development of these autoimmune diseases that target healthy tissues.
The study’s findings lead to toward new treatment approaches for autoimmune diseases, which are increasing in light of a germ-conscious society that regularly destroys many of the previously pervasive microbes that made the immune system more tolerant. “The basic premise of lupus is you have lost normal tolerance to yourself, your own proteins, and DNA,” said Dr. Tracy L. McGaha, Georgia Health Sciences University (GHSU; Augusta, USA) immunologist and corresponding author of the study published ahead of print February 21, 2012, in the journal Proceedings of the [US] National Academy of Sciences.
The investigators discovered that IDO, or indoleomine 2,3-dioxegenase, helps promote tolerance to debris generated by natural cell death and that when IDO is removed from the mixture, the debris triggers an immune response that can induce autoimmune disease. In mice genetically engineered to develop lupus, blocking IDO resulted in earlier, more aggressive disease. “This connects IDO and macrophages. It’s a newly described role for IDO in regulation of tolerance toward self,” Dr. McGaha remarked. Accordingly, increasing IDO production or its downstream effects might be a way to regain lost tolerance, he said.
The researchers assessed activity in the spleen; a hard-working immune organ that constantly filters blood. In a flawlessly organized defense, the entrance to the spleen is surrounded by immune cells that search the blood for viruses, bacteria, even fat and cholesterol floating by.
A neighboring subset of macrophages, which are basically scavengers, then capture and consume the undesirables, according to Dr. McGaha said. Fascinatingly, a lot of what macrophages consume is dead immune cells.
Macrophages also appear to help keep the peace by preventing the immune system from joining the fray. Dr. McGaha earlier found that if he destroyed macrophages, then fed the spleen dead cells, there was inflammation instead of calm. “That tells us there is something inherent in this subset of macrophages that is important for the suppressive process,” Dr. McGaha said referencing the study published in 2011 in the journal Blood.
The new study revealed that IDO is part of that “something.” Efficient elimination of cell debris while keeping nearby immune cells quiet is important because some debris is known to grab the attention of the immune system, According to Dr. McGaha. He noted that it is normal--and healthy--for damaged cells to become targets. “We are really interested in this process of normal cell debris removal because in lupus, it's thought to be one of the main drivers of inflammation,” he said.
The immune system has points of expansion and regulation where it decides whether or not to act. Knowing key points, such as IDO’s regulatory role, provides treatment targets that can interrupt a destructive cascade of immune activity, Dr. McGaha noted. Earlier research has shown evidence of self-attack is present many years before disease symptoms appear, he said.
Environmental hazards, such as a nasty sunburn, can be the first trigger of the abnormal immune response in diseases such as lupus. In healthy individuals, the immune system rises to the occasion of an infection then goes back to baseline. In autoimmune disease, patients tend not to return to normal levels.
GHSU’s Drs. Andrew Mellor and David Munn reported in 1998 in the journal Science that the fetus expresses IDO to help avoid rejection by the mother’s immune system. Following studies have shown tumors also use it and that it could help transplanted organs escape rejection. They suggested that Dr. McGaha evaluate IDO as a regulatory process used by macrophages.
Related Links:
Georgia Health Sciences University
The study’s findings lead to toward new treatment approaches for autoimmune diseases, which are increasing in light of a germ-conscious society that regularly destroys many of the previously pervasive microbes that made the immune system more tolerant. “The basic premise of lupus is you have lost normal tolerance to yourself, your own proteins, and DNA,” said Dr. Tracy L. McGaha, Georgia Health Sciences University (GHSU; Augusta, USA) immunologist and corresponding author of the study published ahead of print February 21, 2012, in the journal Proceedings of the [US] National Academy of Sciences.
The investigators discovered that IDO, or indoleomine 2,3-dioxegenase, helps promote tolerance to debris generated by natural cell death and that when IDO is removed from the mixture, the debris triggers an immune response that can induce autoimmune disease. In mice genetically engineered to develop lupus, blocking IDO resulted in earlier, more aggressive disease. “This connects IDO and macrophages. It’s a newly described role for IDO in regulation of tolerance toward self,” Dr. McGaha remarked. Accordingly, increasing IDO production or its downstream effects might be a way to regain lost tolerance, he said.
The researchers assessed activity in the spleen; a hard-working immune organ that constantly filters blood. In a flawlessly organized defense, the entrance to the spleen is surrounded by immune cells that search the blood for viruses, bacteria, even fat and cholesterol floating by.
A neighboring subset of macrophages, which are basically scavengers, then capture and consume the undesirables, according to Dr. McGaha said. Fascinatingly, a lot of what macrophages consume is dead immune cells.
Macrophages also appear to help keep the peace by preventing the immune system from joining the fray. Dr. McGaha earlier found that if he destroyed macrophages, then fed the spleen dead cells, there was inflammation instead of calm. “That tells us there is something inherent in this subset of macrophages that is important for the suppressive process,” Dr. McGaha said referencing the study published in 2011 in the journal Blood.
The new study revealed that IDO is part of that “something.” Efficient elimination of cell debris while keeping nearby immune cells quiet is important because some debris is known to grab the attention of the immune system, According to Dr. McGaha. He noted that it is normal--and healthy--for damaged cells to become targets. “We are really interested in this process of normal cell debris removal because in lupus, it's thought to be one of the main drivers of inflammation,” he said.
The immune system has points of expansion and regulation where it decides whether or not to act. Knowing key points, such as IDO’s regulatory role, provides treatment targets that can interrupt a destructive cascade of immune activity, Dr. McGaha noted. Earlier research has shown evidence of self-attack is present many years before disease symptoms appear, he said.
Environmental hazards, such as a nasty sunburn, can be the first trigger of the abnormal immune response in diseases such as lupus. In healthy individuals, the immune system rises to the occasion of an infection then goes back to baseline. In autoimmune disease, patients tend not to return to normal levels.
GHSU’s Drs. Andrew Mellor and David Munn reported in 1998 in the journal Science that the fetus expresses IDO to help avoid rejection by the mother’s immune system. Following studies have shown tumors also use it and that it could help transplanted organs escape rejection. They suggested that Dr. McGaha evaluate IDO as a regulatory process used by macrophages.
Related Links:
Georgia Health Sciences University
Latest BioResearch News
- Barcoded DNA Sheds Light on Hidden Complexities in Breast Cancer Detection
- CRISPR-Based Platform Pinpoints Drivers of Acute Myeloid Leukemia in Patient Cells
- Protective Brain Protein Emerges as Biomarker Target in Alzheimer’s Disease
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
Channels
Clinical Chemistry
view channelNew Blood Test Index Offers Earlier Detection of Liver Scarring
Metabolic fatty liver disease is highly prevalent and often silent, yet it can progress to fibrosis, cirrhosis, and liver failure. Current first-line blood test scores frequently return indeterminate results,... Read more
Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
Ovarian cancer is often diagnosed at a late stage because its symptoms are vague and resemble those of more common conditions. Unlike breast cancer, there is currently no reliable screening method, and... Read moreMolecular Diagnostics
view channel
Simple One-Hour Saliva Test Detects Common Cancers
Early detection is critical for improving cancer outcomes, yet many diagnostic tests rely on invasive procedures such as blood draws or biopsies. Researchers are exploring simpler approaches that could... Read more
Blood Test Could Help Guide Treatment Decisions in Germ Cell Tumors
Chemotherapy is often highly effective for germ cell tumors, but in a subset of patients, the disease does not respond well to standard treatment. For these individuals, doctors may consider high-dose... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read moreMicrobiology
view channel
Rapid Sequencing Could Transform Tuberculosis Care
Tuberculosis remains the world’s leading cause of death from a single infectious agent, responsible for more than one million deaths each year. Diagnosing and monitoring the disease can be slow because... Read more
Blood-Based Viral Signature Identified in Crohn’s Disease
Crohn’s disease is a chronic inflammatory intestinal disorder affecting approximately 0.4% of the European population, with symptoms and progression that vary widely. Although viral components of the microbiome... Read morePathology
view channel
Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
Sex differences in Alzheimer’s disease present ongoing diagnostic challenges, with women often experiencing a disproportionate disease burden even when preclinical amyloid-beta levels are similar to men.... Read more
World’s First Optical Microneedle Device to Enable Blood-Sampling-Free Clinical Testing
Blood sampling is one of the most common clinical procedures, but it can be difficult or uncomfortable for many patients, especially older adults or individuals with certain medical conditions.... Read moreTechnology
view channel
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read moreIndustry
view channel
Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more







